OncoMatch/Clinical Trials/NCT06462183
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Is NCT06462183 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies RGT-61159 for adenoid cystic carcinoma.
Treatment: RGT-61159 — Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Biomarker criteria
Allowed: RAS wild-type
if RAS wild-type, an anti-EGFR therapy
Prior therapy
Must have received: fluoropyrimidine-based chemotherapy
must have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidines-, oxaliplatin-, and irinotecan-based chemotherapies
Must have received: oxaliplatin-based chemotherapy
must have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidines-, oxaliplatin-, and irinotecan-based chemotherapies
Must have received: irinotecan-based chemotherapy
must have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidines-, oxaliplatin-, and irinotecan-based chemotherapies
Must have received: anti-VEGF agent
must have been previously treated with, or are not considered candidates for, available therapies including ... anti-VEGF agents
Must have received: anti-EGFR therapy
if RAS wild-type, an anti-EGFR therapy
Cannot have received: MYB inhibitor
Prior treatment with a MYB inhibitor
Lab requirements
Blood counts
adequate hematologic status
Kidney function
renal function
Liver function
liver function and prothrombin time (PT) or INR ≤ 1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
Adequate hematologic status, organ function, renal function, liver function and prothrombin time (PT) or INR ≤ 1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- University of Michigan · Ann Arbor, Michigan
- Washington University School of Medicine · St Louis, Missouri
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, New York
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify